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Left ventricular hypertrophy (LVH) and diastolic dys-
function are very common in patients with chronic
kidney disease (CKD). Aim of this study was to evaluate
the impact of type 2 diabetes on LV geometry and
diastolic function in hypertensive patients with CKD. We
enrolled 288 Caucasian subjects with hypertension and
CKD; of them, 112 had diabetes. Patients with cardio-
vascular (CV) diseases, glomerular filtration rate (GFR)
460mlmin1 per 1.73m2, dialysis treatment and other
major non-CV diseases were excluded. All patients
underwent routine biochemical analyses and echocardio-
graphic examination with tissue Doppler imaging (TDI).
Patients with diabetes had significantly higher LV wall
thicknesses (P¼ 0.0001), relative wall thickness (RWT)
(P¼ 0.0001) and left atrium volume index (P¼ 0.03),
when compared with patients without diabetes. Further,
diabetic patients had very high prevalence of concentric
LVH. Em, evaluated by TDI, was significantly lower in
patients with diabetes (P¼ 0.005). However, the differ-
ence lost statistical significance after correction by
analysis of covariance for RWT. Multiple stepwise linear
regression analysis showed that the variables indepen-
dently associated with Em were: age (b 0.364;
P¼ 0.0001), GFR (beta 0.101; P¼ 0.019), and the pre-
sence of diabetes (b 0.166; P¼ 0.002). Our study showed
that in hypertensive patients with CKD the presence of
diabetes is associated with increased LV-wall thick-
nesses and concentric geometry; further, diabetes
together with renal function (GFR) is associated with
worse diastolic function, independently of potential
confounders, such as age, gender, body mass index
and blood pressure.
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Introduction
Left ventricular hypertrophy (LVH), a frequent
expression of subclinical target-organ damage re-
lated to hypertension, is a very common structural
abnormality in patients with chronic kidney disease
(CKD),1–3 and is independently associated with
cardiovascular (CV) morbidity and mortality.4,5 LV
diastolic dysfunction is also frequent among CKD
patients and is associated with the risk to develop
heart failure and with mortality.6–8
Diabetes, often together with hypertension, repre-
sents today the most common cause of CKD.9 The
negative impact of diabetes on CV prognosis is well
established.10,11 Particularly, diabetes is associated
with coronary artery disease and with LV diastolic
dysfunction.12,13
A recent paper by our group1 confirmed that the
prevalence of LVH is very high in hypertensive
patients with CKD, and is increasingly greater along
with declining renal function. Moreover, in hyperten-
sive patients with CKD, LVH is often characterized by
the simultaneous increase of LV-wall thicknesses,
internal diameters, relative wall thickness (RWT),
and diastolic function is worse in comparison with
hypertensive patients with normal renal function.1
In the present study we evaluate the impact of
type 2 diabetes on LV hypertrophy, geometry and
diastolic function in a group of hypertensive
patients with CKD.
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Patients and methods
The study was carried out in accordance with the
Declaration of Helsinki and institutional guidelines;
enrolled subjects were aware of the investigational
nature of the study and agreed to participate after
informed consent.
Study population
The patients were selected among the subjects
consecutively attending our Internal Medicine,
Nephrology and Hypertension Unit. All subjects
underwent a detailed review of their medical history
and routine laboratory measurements.
Patients having hypertension and CKD, with or
without diabetes, were eligible for this study.
The definition of hypertension was based on the
2007 European Society of Hypertension/European
Society of Cardiology Guidelines.14 Clinic blood
pressure (BP) was considered as the average of three
consecutive measurements using a mercury sphyg-
momanometer after the subjects had been supine
for 5min.
Patients were defined diabetics when fasting
serum glucose level was X126mg per 100ml
and/or plasma glucose 2 h after 75 g glucose load
was X200mg per 100ml,15 they had a previous
diagnosis of diabetes or they were currently using
any diabetes drug.
CKD was defined and stratified using the National
Kidney Foundation—Kidney Disease Outcome
Quality Initiative (K/DOQI) classification:16 stage 1
(kidney damage with normal or increased glomeru-
lar filtration rate (GFR)): GFR X90mlmin1 per
1.73m2; stage 2 (mild CKD): GFR 89–60mlmin1 per
1.73m2; stage 3 (moderate CKD): GFR 59–30ml
min1 per 1.73m2; stage 4 (severe CKD): GFR
29–15mlmin1 per 1.73m2; and stage 5 (kidney
failure): GFR o15mlmin1 per 1.73m2.
Patients on stage 1 and 2 CKD or on dialysis
treatment were excluded from the study.
GFR was estimated by Cockcroft and Gault
equation17 corrected by body surface area. This
method was used for the selection and classification
of patients. In the enrolled subjects GFR was also
estimated by simplified modification of diet in renal
disease (MDRD) Study equation:18 186  serum
creatinine (mg per 100ml)–1.154  age (years)–0.203
( 0.742, if female). The ethnicity factor ( 1.21, if
black) of the equation was not used because all the
subjects enrolled in our study were Caucasian. We
chose to control our results by MDRD equation to
minimize a possible bias deriving from the method
chosen to estimate GFR.
The following exclusion criteria were applied: age
o20 or 475 years, history of CV diseases (previous
coronary artery disease, history of angina or myo-
cardial infarction, abnormalities of cardiac rhythm,
heart failure, ejection fraction (EF)o55%, moderate
or severe valvular diseases, previous transient
ischaemic attack or stroke), GFR 460mlmin1 per
1.73m2, current or previous dialysis treatment,
previous renal transplantation, other major non-CV
diseases. Coronary artery disease was also ruled out,
excluding patients having regional wall motion
abnormalities on echocardiographic examination.
After the application of the exclusion criteria, a
total of 288 Caucasian subjects with hypertension
and CKD were included in the study. Out of the 288
patients, 112 had type 2 diabetes and 176 had not.
Laboratory methods
Determination of routine biochemical parameters
was performed with standard techniques by using
an autoanalyser (Boehringer Mannheim for Hitachi
system 911, Mannheim, Germany).
Echocardiographic methods
The echocardiographic examination was performed
using an Acuson Sequoia 512 system (Siemens,
Mountain View, CA, USA). Images were taken in left
lateral decubitus position. Two-dimensional tar-
geted M-mode echocardiography was performed
using the parasternal long-axis acoustic window to
evaluate left ventricular end-diastolic diameter
(LVEDD), left ventricular end-systolic diameter,
interventricular septum thickness and posterior
wall thickness (PWT) according to the American
Society of Echocardiography recommendations.19
Left atrial diameter was also determined, and left
atrial volume indexed by body surface area (LAVI)
was calculated by the biplane Simpson’s method.20
Only those frames with optimal visualization of
interfaces and showing simultaneous visualization
of septum, left ventricular diameters and posterior
wall were used for readings.
Left ventricular mass (LVM) was determined using
the American Society of Echocardiography-cor-
rected cube formula21 and was indexed by both
body surface area (LVMI) and height elevated by a
power of 2.7 (LVMH2.7) in order to provide a more
stringent allowance for overweight.22 In our labora-
tory, the mean intra-observer variability for LVM
was 8.6%.
LVH was defined as LVM indexed by body surface
area (LVMI) 4125 gm2 in men and 4110 gm2 in
women, as suggested by the 2007 European Society
of Hypertension/European Society of Cardiology
Guidelines.14 RWT was calculated as the ratio of
2PWT/LVEDD. Concentric LVH was defined as LVMI
4125 gm2 in men and4110 gm2 in women, with
RWT 40.45; eccentric LVH was defined as LVMI
4125 gm2 in men and4110 gm2 in women, with
RWT o0.45.
Left ventricular EF was assessed by 2D-echo using
modified Simpson’s rule.23
Diastolic function was evaluated using both
mitral inflow and tissue-Doppler echocardiography,
performed according to the American Society of
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Echocardiography recommendations.24 Mitral in-
flow was assessed in the apical four-chamber
view, using pulsed-wave Doppler echocardiography,
with the Doppler beam aligned parallel to the
direction of flow and the sample volume at the
leaflet tips. From the mitral inflow profile,
the E-wave (E) and A-wave (A) peak velocities, E/
A ratio and E-deceleration time were measured.
Isovolumic relaxation time was calculated between
aortic valve closure and the start of E-wave.
Tissue Doppler imaging (TDI) of the mitral
annulus was obtained from the apical four-chamber
view, using a 1- to 2-mm sample volume placed in
the lateral mitral valve annulus, to evaluate early
diastolic myocardial velocity (Em) and atrial
diastolic myocardial velocity (Am). The E/Em ratio
was also calculated.
We decided to evaluate diastolic function princi-
pally by means of TDI, as parameters measured by
TDI are more preload-independent than those
measured by mitral inflow;25 further, Em is inversely
related to myocardial fibrosis.25 E/Em is considered
as a good predictor of elevated LV filling pressure.26
Echocardiographic data are expressed as the
average of five consecutive cardiac cycles. Images
were read by a single cardiologist, who was blinded
to the patient’s clinical characteristics.
Statistics
Data for continuous variables are given as mean±
standard deviation.
Differences between groups were evaluated, when
appropriate, using analysis of variance and the
independent-sample Student’s t-test with Bonferroni
correction, for continuous variables and the w2-test,
with Yates’ correction, for the categorical variables.
When appropriate, differences were adjusted, by
analysis of covariance (ANCOVA), for body mass
index (BMI).
Univariate associations between the variables
were assessed by the Pearson’s correlation coeffi-
cients and multiple stepwise linear regression
analysis. This latter was performed in the whole
group of 288 patients considering Em as the
dependent variable, and including in the statistical
model age, sex, BMI, systolic and diastolic BP, GFR,
haemoglobin, LAVI and type 2 diabetes (this latter
included as a dichotomous variable). Multiple
regression analysis was also repeated adding RWT
to the model, and replacing GFR with serum
creatinine and replacing GFR estimated by Cockcroft
and Gault equation with GFR estimated by MDRD
equation.
The null hypothesis was rejected at a two-tailed
Pp0.05.
The statistical analyses were performed using
the SYSTAT DATA software package, version 5.2
(Systat, Evanston, IL, USA).
Results
The main demographic and clinical data of the
patients are synthesized in Table 1. There were no
significant differences in age, distribution of sex,
GFR, haemoglobin, systolic and diastolic BP, pulse
pressure and known duration of both hypertension
and CKD. BMI was higher in patients with type 2
diabetes (P¼ 0.036).
All patients received pharmacological treatment.
Anti-hypertensive treatment for the patients with
type 2 diabetes was as follows: 30% ACE inhibitors
(alone or in combination with a diuretic); 33% AT1
blockers (alone and in combination with a diuretic);
5% b-blockers or a-b-blockers; 1% a-blockers; 10%
calcium-channel blockers; 2% diuretic alone; 19% a
combination of two or more of these drugs. Use of
the different classes of anti-hypertensive drugs was
not different in comparison with patients without
diabetes (P¼ 0.93).
Around 22% of the whole sample was on current
recombinant human erythropoietin treatment. In the
group of patients with type 2 diabetes, 67% received
Table 1 Principal demographic and clinical data (mean±s.d.) of 112 hypertensive patients with chronic kidney disease and with type 2
diabetes, and of 176 hypertensive patients with chronic kidney disease and without diabetes
Type 2 diabetic
patients (N¼ 112)
Non-diabetic
patients (N¼176)
P
Age, years 63.2±8.4 62.9±13.7 0.852
Males/females 70/42 109/67 0.982
Body mass index, kgm2 27.6±3.7 26.7±3.8 0.036
Serum creatinine, mmol l1 254.6±125.5 298.8±185.6 0.029
GFRCG, mlmin
1 per 1.73m2 29.2±12.35 27.9±15.1 0.435
GFRMDRD, mlmin
1 per 1.73m2 25.8±11.9 25.9±16.2 0.969
Haemoglobin, g l1 126±12 125±14 0.375
Systolic blood pressure, mmHg 146±19 143.2±19 0.212
Diastolic blood pressure, mmHg 80.2±11.9 80.8±13.7 0.687
Pulse pressure, mmHg 65.9±16.4 62.4±18.6 0.104
Known duration of hypertension, years 12.1±9.3 11.8±8.5 0.779
Known duration of chronic kidney disease, years 2.95±3.5 3.8±5.3 0.134
Abbreviations: GFRCG, glomerular filtration rate estimated by Cockcroft–Gault equation; GFRMDRD, glomerular filtration rate estimated by MDRD
equation.
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insulin therapy, and mean value of HbA1c was
7.3%.
Table 2 shows the main echocardiographic find-
ings. Patients with type 2 diabetes had significantly
higher interventricular septum thickness, PWT
(P¼ 0.0001 for both), left atrium diameter
(P¼ 0.014) and LAVI (P¼ 0.03) when compared
with patients without diabetes. Further, RWT was
significantly higher in patients with type 2 diabetes,
also after correction by ANCOVA for BMI (Table 2).
LVEDD, left ventricular end-systolic diameter and
EF were not significantly different comparing the
two groups. LVMI and LVMH2.7 were slightly higher
in patients with type 2 diabetes, but the difference
did not reach statistical significance.
In regard to diastolic function, parameters eval-
uated by mitral inflow (E/A, deceleration time and
isovolumic relaxation time) were not significantly
different comparing patients with and without type
2 diabetes (Table 2). TDI showed that Em was
significantly lower in patients with type 2 diabetes,
also after correction by ANCOVA for BMI or for
LAVI. When we adjusted by ANCOVA for RWT, the
difference lost statistical significance (Table 2); thus,
the differences in Em values were largely explained
by the higher RWT of patients with type 2 diabetes.
Further, in diabetic patients a highly significant
inverse correlation between Em and RWTwas found
(Figure 1); Em was also inversely correlated with
LAVI (r¼0.188; Po0.01).
Moreover, the ratio E/Em was significantly higher
in patients with type 2 diabetes (P¼ 0.001).
We further analyzed the grading of diastolic
dysfunction20 in patients with and without diabetes.
Overall, the prevalence of diastolic dysfunction was
significantly higher in patients with type 2 diabetes
(100/112 (89.3%)) than in those without diabetes
(129/176 (73.3%)) (P¼ 0.002). The prevalence of the
different grades of diastolic dysfunction is shown in
Table 3. Of note, only a minority of patients had
diastolic dysfunction grade III or IV; this can be
chiefly explained bearing in mind that all the
patients with heart failure were excluded from the
study. However, a slightly higher (although not
significant) prevalence of more advanced grades of
diastolic dysfunction was found in patients with
type 2 diabetes (Table 3); the slightly higher
prevalence of diastolic dysfunction grade II and III
may also contribute to explain why there was no
significant difference of mitral inflow measurements
Table 2 Echocardiographic data (mean±s.d.) of 112 hypertensive patients with chronic kidney disease and with type 2 diabetes, and of
176 hypertensive patients with chronic kidney disease and without diabetes
Type 2 diabetic
patients (N¼ 112)
Non-diabetic
patients (N¼ 176)
P
Left ventricular end-diastolic diameter, mm 50.69±5.5 51.7±5.56 0.140
Left ventricular end-systolic diameter, mm 32.15±5 33±5.04 0.153
Ejection fraction, % 66.19±5.1 65.43±5.5 0.243
Interventricular septum thickness, mm 12.27±2.1 11.42±1.86 0.0001
Posterior wall thickness, mm 11.84±2.05 10.97±1.85 0.0001
LVMI, gm2 137.3±40.4 130.8±42.3 0.197
LVMH2.7, gm2.7 65.9±21 61.6±20.5 0.081
Relative wall thickness 0.472±0.09 0.426±0.07 0.0001*
Left atrium diameter, mm 39.2±5.5 37.5±5.9 0.014
LAVI, mlm2 36.2±16 31.8±18 0.03
E/A 0.795±0.36 0.814±0.3 0.629
DT, ms1 310.5±90 304.4±85 0.537
IVRT, ms1 114±24.4 117±24.5 0.302
Em, ms1 0.078±0.023 0.087±0.028 0.005w, #, z
E/Em 9.65±5.53 7.9±3.32 0.001
Abbreviations: A, A-wave peak velocity; ANCOVA, analysis of covariance; DT, E-wave deceleration time; E, E-wave peak velocity; Em, early
diastolic myocardial velocity; IVRT, isovolumic relaxation time; LAVI, left atrial volume indexed by body surface area; LVMH2.7, left ventricular
mass indexed by height2.7; LVMI, left ventricular mass indexed by body surface.
*P¼0.0001 also after adjustment by ANCOVA for body mass index.
wP¼ 0.013 after adjustment by ANCOVA for body mass index.
#P¼0.01 after adjustment by ANCOVA for LAVI.
zP¼0.28 after adjustment by ANCOVA for relative wall thickness.
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Figure 1 Univariate correlation between early diastolic myocar-
dial velocity (Em) and relative wall thickness (RWT) in 112
hypertensive patients with chronic kidney disease and type 2
diabetes.
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comparing patients with and without diabetes
(Table 2).
As shown in Figure 2, the prevalence of LVH was
63.39% (N¼ 71/112) in patients with type 2 diabetes
and 51.13% (N¼ 90/176) in those without diabetes,
but the difference was only of borderline signifi-
cance (P¼ 0.055).
The distribution of concentric and eccentric
patterns of LVH was significantly different compar-
ing patients with and without diabetes (Po0.0001—
Figure 3), as diabetic patients had a very high
prevalence of concentric LVH (73.23%).
The multiple stepwise linear regression analysis,
performed considering Em as the dependent vari-
able, and including in the statistical model age, sex,
BMI, systolic and diastolic BP, GFR (estimated by
Cockroft-Gault equation corrected by body surface
area), haemoglobin, LAVI and type 2 diabetes
(included as dichotomous variable), showed that
the variables independently associated with Em
were: age (b¼ 0.364; P¼ 0.0001), GFR (b¼ 0.101;
P¼ 0.019) and the presence of diabetes (b¼ 0.166;
P¼ 0.002) (Table 4). Further, when we added RWT
to the multivariate model, an independent inverse
relationship between RWT and Em was found (b
0.340; P¼ 0.0001), and the relationship between
diabetes and Em lost statistical significance
(P¼ 0.146).
Similar results were obtained when GFR
estimated by Cockroft–Gault equation was replaced,
respectively, by GFR estimated by MDRD equation
or by serum creatinine (data not shown).
Discussion
In this study we evaluated the impact of type 2
diabetes on LV structure and diastolic function in a
Table 3 Prevalence of different grades of diastolic dysfunction in
112 hypertensive patients with chronic kidney disease and with
type 2 diabetes, and in 176 hypertensive patients with chronic
kidney disease and without diabetes
Type 2 diabetic
patients
(N¼ 112)
Non-diabetic
patients
(N¼ 176)
Prevalence of diastolic
dysfunction, n (%)
100/112 (89.3) 129/176 (73.3)*
Grade I, n (%) 85/100 (85) 121/129 (93.8)
Grade II, n (%) 9/100 (9) 6/129 (4.65)
Grade III, n (%) 6/100 (6) 2/129 (1.55)
Grade IV, n (%) 0/100 (0) 0/129 (0)
*P¼0.002 (P¼ 0.108 comparing the prevalence of the grades of
diastolic dysfunction between patients with and without diabetes).
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Figure 2 Prevalence of left ventricular hypertrophy in hyperten-
sive patients with chronic kidney disease, with and without type
2 diabetes.
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Figure 3 Prevalence of concentric and eccentric patterns of left
ventricular hypertrophy in hypertensive patients with chronic
kidney disease, with and without type 2 diabetes. Dark grey-
concentric LVH; light grey¼ eccentric LVH.
Table 4 Multivariate correlates of early diastolic myocardial
velocity in the whole study population of 288 hypertensive
patients with chronic kidney disease
Regression
coefficient
Standard
error
Standard regression
coefficient (beta)
P
Age 0.00008 0.00001 0.364 0.0001
GFR 0.00029 0.00012 0.101 0.019
Diabetes 0.00888 0.00286 0.166 0.002
Abbreviations: Em, early diastolic myocardial velocity; GFR, glomer-
ular filtration rate estimated by Cockcroft–Gault equation corrected by
body surface area.
Besides the variables listed in the table, the other covariates were sex,
body mass index, systolic and diastolic blood pressure, haemoglobin
and left atrial volume indexed by body surface area. When relative
wall thickness (RWT) was added to the multivariate model, an
independent inverse relationship between RWT and Em was found
(b¼ 0.340; P¼0.0001), and the relationship between diabetes and Em
lost statistical significance (P¼ 0.146). The inclusion into the model
of serum creatinine or GFR estimated by MDRD equation, instead of
GFR estimated by Cockroft–Gault equation, did not significantly
change the results.
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group of hypertensive patients with CKD. Patients
with and without diabetes were not different in
regard to several clinical characteristics, including
BP, GFR, duration of hypertension and of CKD.
The main findings of our study are the following:
(1) type 2 diabetes is associated with increased
LV-wall thicknesses and concentric geometry;
(2) type 2 diabetes, together with renal function
(GFR), is associated with worse diastolic
function independently of potential confoun-
ders, such as age, sex, BMI and BP.
In hypertensive patients, concomitant diabetes
has been associated with higher LVM, more con-
centric geometry and impaired systolic and diastolic
function.27,28 Moreover, diabetes has a negative
impact on treatment-induced changes in LV struc-
ture and function in hypertensives with LVH.29
In the Strong Heart Study,27 which involved a
wide group of American Indians, diabetic subjects
had higher LVM, interventricular septum thickness,
PWT and RWT in comparison with subjects without
diabetes, with no difference in LV chamber size.
Similar results were obtained in the HYperGEN
Study,28 in which diabetic hypertensives had higher
LVM and more concentric geometry when compared
with non-diabetic hypertensives (again in this study
diabetics had higher LVM, interventricular septum
thickness, PWT and RWT but there was no differ-
ence with regard to LV diameter). However, in this
study the relation of diabetes with LVH lost
statistical significance when duration of hyperten-
sion was included in the statistical analysis.28 In
regard to LV geometry, our results are consistent
with those by the Strong Heart Study27 and the
HYperGEN Study.28 In fact, in our study, patients
with diabetes had higher LV wall thicknesses (but
not diameters), higher RWT and higher prevalence
of concentric LVH when compared with patients
without diabetes (Table 2, Figure 3). Although we
observed a trend toward higher values of LVMI and
LVMH2.7, and higher prevalence of LVH in diabetic
patients, these differences did not reach statistical
significance. We cannot exclude that the relative
small sample size could influence these findings.
Further, diabetic patients had higher LV wall
thicknesses, but LVEDD, although the difference
was not significant, was slightly lower in compar-
ison with patients without diabetes. As the value of
LVEDD is part of the formula to calculate LVM, this
may explain why the differences of LVMI, LVMH2.7
and LVH prevalence did not reach statistical
significance between the two groups.
Scant information is available in the literature
about the influence of diabetes on LV structure and
function in patients with CKD.
A study by Miyazato et al.8 focused this issue in a
sample of 67 patients with CKD (34 of whom had
diabetes) and in 134 essential hypertensives with
normal renal function (67 diabetics). In this study
LVH was associated mainly with CKD, with no
further influence of diabetes. In contrast, diastolic
dysfunction (defined in this study as decreased E/A
and prolonged deceleration time) was promoted by
both CKD and diabetes, and the impact of diabetes
appeared somewhat stronger than that of CKD.8 Our
study, in agreement with our previous results,1,7
confirms that renal function is associated with
impaired diastolic function and is independently
related with Em, a parameter that has been demon-
strated to be inversely related to the degree of
fibrosis in ischemic, as well as in normal myocardial
segments.24 Moreover, in our study, also type 2
diabetes was independently associated with Em,
and patients with diabetes had significantly lower
Em values in comparison with non-diabetic pa-
tients. However, after correction by ANCOVA for
RWT, this difference disappeared, showing that the
negative impact of type 2 diabetes on diastole was
largely explained by the association with increased
RWT and concentric geometry. This was further
confirmed when we added RWT to the multivariate
model: the relationship between diabetes and Em
lost statistical significance, highlighting an inde-
pendent inverse relationship between RWT and Em.
Further, patients with type 2 diabetes had higher
left atrium diameter, higher LAVI, higher E/Em ratio
and higher prevalence of diastolic dysfunction when
compared with patients without diabetes (Tables 2
and 3). Left atrium size, expressed in clinical practice
as LAVI, is considered as a morphological expression
of diastolic dysfunction, and as a marker of chroni-
city of increased LV filling pressure.20 It has been
demonstrated that the index E/Em has a good
correlation with LV filling pressure, and this correla-
tion has been reported to be higher in comparison
with any other Doppler parameters, especially when
systolic function (EF) is preserved.25,26 In this regard,
it is to note that all the patients here studied had
normal EF. The mean value of E/Em in the subgroup
with diabetes was 9.65, near to the cut-off value of 10,
which is considered a good single predictor of
elevated LV filling pressure.25,26 Taken together, the
results of our study suggest that in hypertensive
patients with CKD and type 2 diabetes the impair-
ment of diastolic function, accompanied by left
atrium enlargement and increase of LV filling
pressure, can be due to the development of con-
centric geometry with increased myocardial fibrosis.
Autopsy studies have shown increased myocar-
dial fibrosis in patients with hypertension and
diabetes,30 as well as in patients with renal fail-
ure.31,32 Experimental studies suggest that increased
advanced glycation end-product formation asso-
ciated with hyperglycaemia may be linked with
increased myocardial stiffening and dysfunction.33,34
Increased myocardial fibrosis presumably contributes
to myocardial ischaemia due to the reduction in
capillary density and coronary reserve.32 Recently,
even subclinical renal damage has been associated
with impaired coronary flow reserve.35 Further,
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increased myocardial fibrosis has a central role in the
alterations of diastolic function.
Study limitations
Our study had a cross-sectional design, so it does not
allow us to draw causal relationships. Further, our
study population consisted of a relatively small
sample of only Caucasian subjects. This limits the
applicability of our results to other racial or ethnic
groups, but it is noteworthy that results similar to
ours were obtained in American Indians participating
to the Strong Heart Study.27 We evaluated only clinic
BP, whereas 24-h ambulatory BP was not assessed,
and associations between echocardiographic variables
and arterial stiffness or albuminuria were not tested,
because these data were available only for a minority
of patients. Lastly, as all our patients received anti-
hypertensive drugs, we have to acknowledge the
possible influence of the pharmacological treatment
on our results. In this regard, use of the different
classes of anti-hypertensive drugs was not different in
patients with and without diabetes.
Conclusions
In summary, our study highlights that hypertensive
patients with type 2 diabetes and CKD are character-
ized by impaired LV diastolic function, which is
largely explained by the increase of LV wall thick-
nesses and by the development of concentric LVH.
These results, which are in agreement with previous
findings in diabetic hypertensive patients,27,28 may
suggest that an echocardiographic examination should
routinely be performed in patients having hyperten-
sion together with type 2 diabetes and CKD. Indeed,
even if the patients of our sample were all free of CV
diseases and heart failure, and even if renal dysfunc-
tion was not extremely advanced, there was high
probability to detect LV changes.
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